Dren Bio is at the forefront of developing innovative antibody therapeutics aimed at selectively depleting pathogenic cells and other disease-causing agents. The company’s pipeline includes two first-in-class clinical programs: DR-01 and DR-0201. DR-01 is designed to target and deplete autoreactive CD8 T cells, which are implicated in various hematological and autoimmune diseases, and is currently being evaluated in patients with large granular lymphocytic leukemia and cytotoxic lymphoma. Meanwhile, DR-0201 is a bispecific antibody that engages myeloid cells to induce deep B cell depletion through targeted phagocytosis, showing promise in preclinical studies for safety and efficacy. Both programs aim to reset the immune system in patients suffering from autoimmune diseases.

Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform underpins its therapeutic development, utilizing bispecific antibodies that activate myeloid cells in a controlled manner when in the presence of target antigens. This technology allows for the targeted depletion of pathogenic cells and protein aggregates, potentially offering improved safety profiles compared to traditional therapies like T-cell engagers and antibody-drug conjugates. The platform is versatile, supporting a range of preclinical programs across oncology, immunology, and neurology, and is expected to lead to significant advancements in treating serious diseases.

United States

Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.

Dren Bio

Company Details